# Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS

> **NCT03221621** · PHASE4 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 128 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **PROCEDURE:** Wide Excision
- **DRUG:** Adalimumab Injection

## Key facts

- **NCT ID:** NCT03221621
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-31
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2019-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221621, "Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03221621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*